Business Archives - Green Market Report

Kaitlin DomangueKaitlin DomangueOctober 20, 2020
employment-people-services-1280x853.jpg

6min4200

The cannabis industry is one of the fastest growing industries in the world today, but especially in the United States. As more and more states begin legalizing marijuana, the need for workers continues to go up. Marijuana Business Daily estimates that jobs in the industry will jump from 240,000 to 295,000 in 2020 alone. This represents a 50% increase over 2019’s industry growth, which estimated the year to start with 165,000 jobs and end with 210,000. MJBiz Daily considers those in the industry to be those who work directly with the plant like budtenders, all the way up to ancillary positions like lawyers and consultants. 

Many people are leaving their current fields to join the rapidly growing cannabis industry, and a lot of them are taking their existing skills with them. Registered nurses become cannabis nurses and begin educating patients, retail managers transition to dispensary managers, traditional horticulturists join cultivation teams, and tech workers become part of a cannabis software team. The wonderful thing about this industry is that while the cannabis plant is the most important part, it isn’t the only part. The cannabis industry relies on truck drivers to transport product, security teams to ensure employee and product safety, content creators to create content that meets FDA guidelines, and more. Without these positions, the cannabis industry could not get itself off the ground. 

Vangst is the cannabis industry’s leading recruitment platform, and they are hosting a virtual cannabis job fair next month. They already have over 3,000 job seekers and more than 50 leading companies looking to connect with each other. Job seekers can expect to talk with people from top companies like Cresco Labs, Flowhub, LeafLink, and Native Roots. The virtual fair begins on October 21st and goes until the 22nd. 

Just because this is a virtual event doesn’t mean it isn’t worthwhile. While it isn’t what most are used to, Vangst is coming up with innovative techniques to allow job seekers and employers to get the most out of their experience, even through a virtual setting. They are offering two different educational tracks to follow, the Main Stage track which features educational content and panels from some of the leading voices in the industry. The Vangst track is specifically for cannabis recruitment topics, including resume and interview prep, career specific Q&As, and industry speak. In addition to these two tracks, job seekers can connect with employers through their virtual booth, as well as virtual networking hubs. 

One of the most unique aspects of the virtual career fair is Vangst’s partnership with The Last Prisoner Project, an organization that fights to end unfair prison sentences for nonviolent cannabis offenses. The event will host a social equity networking space intended to empower job seekers to connect with unique social equity and employment programs offered by employers, volunteer, and advocacy groups that are present at the event. Social equity job seekers will also receive wait priority from job seekers in order to put them at the front of the line. In addition to Vangst’s partnership with The Last Prisoner Project, they have also partnered with Mission Green (an extension of The Weldon Project) and California Cannabis Coalition. The Last Prisoner Project’s founder, Steve DeAngelo, will kick-off the two day event with a social equity panel on “How Employees, Entrepreneurs, and Advocates Can Participate in Social Equity Programming.” Vangst is truly trying to drive home the point that the cannabis industry has a place for everyone, and aims to make employment as accessible as possible to all people. 

Vangst is not the only company to host a virtual event due to the coronavirus pandemic. Since people began staying home more, there have been tons of virtual events taking place. MJBizCon, which is said to be the largest cannabis conference in the world, recently canceled all of their in-person events and moved to a five-week digital conference and trade show instead, starting on November 2nd and finishing up with their original dates of December 2nd-4th. Even before the decision was made to cancel the in-person events, attendees had the option to opt for a fully online event. 

“We organized this virtual career fair in the hopes that it will introduce job seekers to the full range of available roles within cannabis,” said Vangst CEO Karson Humiston. “We want to provide exposure to every type of opportunity – from plant-touching to ancillary, cultivation to tech, and everything in between – and give them the tools they need to join this growing industry, no matter what their path is.”


Kaitlin DomangueKaitlin DomangueOctober 19, 2020
daily_hit004-1280x533.png

2min2910

It’s time for your Daily Hit of cannabis financial news for October 19th, 2020. 

On the Site

Mydecine Innovations Group 

Mydecine Innovations Group, Inc, (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”) announced the appointment of UK-based Boustead Capital Markets LLP (“Boustead”) to commence the dual listing process on the London Stock Exchange (“LSE” or the “Exchange”) for the admission of the Company’s common shares to the Standard Segment of the Official List’s Main Market.

In Other News 

Acreage Holdings Inc. (CSE:ACRG.A.U, ACRG.B.U)(OTCQX: ACRHF, ACRDF), announced this morning they retired a short-term strategic financing. The financing was announced in June 2020 and the company paid an aggregate amount of approximately $18 million in order to retire the full balance and accrued interest. 

The finances were used to close the acquisition of vertically-integrated options in New Jersey. The completion of this agreement ultimately rearranged Acreage’s capital structure and significantly reduced their debt outstanding. 


StaffStaffOctober 19, 2020
shutterstock_431001775-1280x850.jpg

3min3570

Mydecine Innovations Group, Inc, (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”) announced the appointment of UK-based Boustead Capital Markets LLP (“Boustead”) to commence the dual listing process on the London Stock Exchange (“LSE” or the “Exchange”) for the admission of the Company’s common shares to the Standard Segment of the Official List’s Main Market.

Among the factors considered by the Company in pursuing the dual listing, Mydecine™ noted that the LSE currently has a limited number of sizable psychedelics-focused biotech companies. Mydecine, as a contributing member to Drug Science UK, the only completely independent, science-led drugs charity, believes the LSE listing will provide UK and European investors with greater, more local exposure to a new high-quality investment choice of a business type not currently available on the Exchange.

Highlights

Mydecine’s appointment of Boustead enables it to commence the LSE listing process and act on its intention for the Company’s common shares to trade on the Main Market in the next few months. In addition to its current listings in Canada, the United States, and Germany, the Company believes that a listing on the LSE makes it well-positioned to bring European investors into the Company’s share register.

The LSE listing is expected to provide all investors access and exposure to:

  • European Investor base in what the Company believes are Psychedelic-friendly countries such as the Netherlands, United Kingdom, Austria, and Portugal, to name a few
  • Support early and late-phase clinical trials
  • Expansion of the Company’s telehealth platform; Mindleap Health
  • Further development of extensive IP portfolio
  • Furthering the development of novel types of psilocybin-based medicine and unique formulations

Josh Bartch, CEO & Chairman of Mydecine Innovations Group, commented, “The Board of Directors has met a number of times deciding the best route and venue for the new listing of the Company’s securities, adding to our focus on shareholder value. We decided the LSE represented the best stock exchange for our investors, shareholders, and the ongoing growth of the Company. Additionally, it provides a great platform to measurably advance our investor reach within the European investor community. A LSE Listing offers a number of opportunities to fast-track further potential listings to exchanges such as NASDAQ or NYSE. Mydecine Innovations Group has a global reach through the Company’s various planned clinical trials, research facilities, partners and scientific advisors, some of which are located directly in the UK.”


Kaitlin DomangueKaitlin DomangueOctober 16, 2020
zynerba-homepage-1280x580.jpg

5min12590

Zynerba Pharmaceuticals (NASDAQ:ZYNE) was up 6% after data from a Phase 2 BRIGHT study showed CBD to have significant potential for patients with Autism Spectrum Disorder. The study looked at some of the classic behaviors associated with autism spectrum disorder (ASD), and whether or not CBD affected them. The open label data will be presented at the virtual Joint 16th International Child Neurology Congress (ICNC) & 49th Annual Child Neurology Society (CNS) Meeting.

In the study, researchers used the transdermal gel Zygel for all participants, then analyzed their behavior. All of the subjects are children and adolescents with moderate to severe Autism Spectrum Disorder or ASD. The data reveals that the transdermal patch created a significant improvement in behaviors, based on the Autism Impact Measure or AIM. AIM is a traditionally-used questionnaire for caregivers that assesses behaviors associated with autism. According to a resource originally published in the Journal of Autism and Developmental Disorders, the AIM questionnaire consists of 41 items on a 5-point Likert-type scale, looking at both frequency and impact. The questionnaire examines things like peer interaction, atypical behavior, communication, social reciprocity, and communication. AIM can be used to establish a baseline for people with autism, and allow researchers to better indicate if any improvements have been made and to what degree. 

The study’s participants ranged from three to 18 years old, and enrolled all patients had Clinical Global Impression (CGI)-Severity score of ≥4 (moderate or greater) and Aberrant Behavior Checklist-Community (ABC-C) Irritability score ≥18. The study consisted of a 14-week treatment period and a six month extension period, totaling 38 weeks of observation at some level. Researchers looked at caregiver/parental stress, the AIM questionnaire, as well as caregiver reported behavioral problems. The authors of the study concluded that Zygel was beneficial in all of the ASD measures analyzed. The press release stated that there were “clinically meaningful improvements” at 14 weeks out from baseline, with 57% of participants assessed as “very much improved” or “much improved.” Also, the application was very well tolerated by the study’s participants. This is important because people with autism commonly have allergies and/or sensitive bodies, introducing new products may be helpful or harmful depending on what they are. 

The majority of participants showed improvement across all three areas of behavioral traits: behavioral, social, and emotional. In the behavioral category, caregivers cited patterns like aggression, refusing to go to school, self-harm, and repetitive phrases as areas of concern. The study reported 69% of subjects considered these behaviors be “improved” after the 14 week treatment period. The social arena showed an improvement for 63% of patients, and 72% of participants claimed an emotional improvement. These assess areas like lack of personal space, fear of new people, minimal social engagement, easily offended, little self-regulation of emotions, and anxiety. 

“The Phase 2 BRIGHT trial provides the first clinical evidence of the potential for Zygel to improve behavioral symptomology in a group of highly symptomatic pediatric and adolescent patients with ASD,” said Helen Heussler, FRACP, Associate Professor at Children’s Health Queensland, Medical Director Child Development and principal investigator in the BRIGHT trial. “In these children receiving Zygel, the observed changes from baseline are promising. In particular, the improvements seen in core symptoms of autism, as specifically assessed by the Autism Impact Measure, are of special interest. Though open label, these results are compelling and we look forward to continuing the evaluation of Zygel in ASD in future placebo-controlled clinical trials.”

Zynerba is a global pharmaceutical technology company that produces transdermal cannabinoid therapies for rare or near-rare neuropsychiatric disorders, including Fragile X Syndrome, autism spectrum disorder, different eplieptic conditions, and 22q11.2 syndrome. 


StaffStaffOctober 16, 2020
Shift.jpg

5min6340

Colorado cannabis company  Dalwhinnie acquired Shift Genuine Cannabis brand, including Shift Refinery. The company did not disclose the valuation of the acquisition.  

“The acquisition was an obvious next step for Dalwhinnie,” said Terrance Mendez, Chief Executive Officer. “Acquiring full control of Shift Genuine Cannabis is an integral part of our plan to provide consumers with the highest quality cannabis products.”

Shift Genuine Cannabis is a leading producer of premium cannabis cultivated at Dalwhinnie’s world-class facility in western Colorado, which also produces a longer-cured flower, Dalwhinnie Farms Connoisseur Grade Cannabis. The Shift brand is available at over 100 dispensaries across Colorado, including the Dalwhinnie Farms flagship boutique in Aspen. 

Shift Genuine Cannabis was established in 2010 to serve Colorado’s cannabis market and is now widely recognized for creating unique cultivars. It recently ranked as Colorado’s second best-selling bulk flower throughout summer 2020, according to wholesale marketplace LeafLink. 

 Shift Refinery is an elite extraction center, producing high quality recreational and medical vaporizer cartridges and concentrates such as distillates and the award-winning live resin Space Ape, which recently earned third place for Best Rec Badder in the 2020 Connoisseur Cup.

 “We’re focused on combining the best cultivation practices with the best extraction technology, which creates a winning combination for our consumer,” said Mr. Mendez.

 At its state-of-the-art facility in Colorado’s Rocky Mountain West, Dalwhinnie takes a sustainable approach to cultivation, using geothermal cooling and irrigation systems that capture and return clean water to the nearby Uncompahgre River. 

 “While the acquisition primarily merges business operations, it’s also a merger of a consumer-focused mindset,” said Ashley Grace, Chief Revenue Officer. “The Shift brand has long been committed to the wellness of its consumers while maintaining the highest standard of excellence. Similarly, our longer-cured, Dalwhinnie Farms brand seeks to deliver a connoisseur grade cannabis experience to a more discerning consumer.  This acquisition primes both brands to flourish and grow with the support of one another.”


Noemi GonzalesNoemi GonzalesOctober 16, 2020
792399-v0_5-GMR-BC-FB.png

4min6770

“High Magick: A Guide to Cannabis in Ritual & Mysticism”

By Philip H. Farber

-Topic Focus-
Now this book seems like a proper fit for the spooky Halloween season as “High Magick” is a modern cannabis grimoire in the sense that it focuses on combining marijuana use and exploring the topic of magic and other related mystical concepts.

Here you will find such a fascinating range of topics varying from how to leverage cannabis when it comes to magical rituals, taking a look at bizarre characters such as Timothy Leary and Aleister Crowley, and how to make various concoctions and elixirs.

It’s always incredibly engaging to take a look a the world of cannabis from different angles ranging from the scientific to the more esoteric.

Let’s crack this tome and see what we have on our hands with this one!

-About the Author-

Author of “High Magick” Philip H. Farber has written several other books such as “Meta-Magick: The Book of Atem: Achieving New States of Consciousness Through NLP, Neuroscience, and Ritual” and “Futureritual: Magick for the 21st Century”.

He has had a wide variety of content that has appeared in an array of publications such as Green Egg Magazine, The Journal of Hypnotism, Hypnosis Today, Mondo 2000, High Times, Paradigm Shift, Reality Sandwich, and many others. He has also put together a variety of DVD courses focusing on Magick oriented topics.
Phil also spends his time as an instructor for Maybe Logic Academy (www.maybelogic.org), a Certified Hypnotist and a Licensed Trainer of Neuro-linguistic Programming, with a private practice in New York’s Hudson Valley.

-Reading Experience-

If you have a fascination with magick and the esoteric then you will find the step-by-step guides that focus on various rituals to be quite interesting and detailed as well as the exploration of healing applications, meditation practices, and so much more.

It is rare to find a book that works to blend the topics of magick and cannabis so it is quite interesting and fun to explore what “High Magick” has to offer on the subject and is written in a way that helps you to grasp the passion and depth of knowledge the author possesses.

Take a look at the index in this book and you will find that this book dives into an array of fascinating topics and flows smoothly from one chapter to the next.

-Summary-

You can enjoy a fun and unique read while also learning about the fascinating relationship between magick and cannabis use that author Philip Farber has put together for our enjoyment and education.

The book touches on a wide array of topics ranging from the history fo magick and cannabis, purported mystical characters from the past, how to make elixirs, ritual guides, and so much more in a fashion that is both entertaining and illuminating to read.

Start your own journey to better grasp the relationship between magick and cannabis by getting your own copy of “High Magick” here:


Video StaffVideo StaffOctober 16, 2020

4min7720

Markets were closed this past monday to celebrate Columbus day or Indigenous Peoples day. Earnings season is starting to pick up and several companies began releasing numbers this week. Some official and some unaudited and unofficial

Aphria (APHA) reported its first-quarter revenue of $69.6 million in the first quarter for fiscal year 2021. This represents strong growth, showing a 23% increase from the prior quarter, as well as the sixth consecutive quarter of growth. Aphria reported a net loss of $5.1 million for the first fiscal quarter, showing a significant decrease from the prior quarter’s loss of $98.8 million. 

Harborside Inc. (OTCQX: HBORF) released preliminary unaudited third-quarter 2020 results for the period ending September 30 with gross revenue for the quarter is expected to exceed $18.5 million.  Net revenue for the quarter ending in June was $15.2 million with net losses of $1.7 million.  The company did not release any information with regards to profits or losses. investors may need to be reminded that Harborside changed its ticker symbol from “HSDEF” to “HBORF” on the OTCQX market effective today October 7, 2020.

cbdMD, Inc. (NYSE: YCBD) reported preliminary financial results for the fourth quarter of and the year ending September 30, 2020. The company said that net sales revenue for fiscal 2020 is expected to range between $41.7 and $41.8 compared to $23.7 million in fiscal 2019. cbdMD also stated that its net sales revenue for the fourth quarter of fiscal 2020 are expected to range between $11.5 and $11.7 million compared to $9.54 million in the fourth quarter of fiscal 2019. the company did not report any profit or loss numbers.

The Valens Company Inc. (TSX: VLNS) (OTCQX: VLNCF) reported its third-quarter financial results for the period ended August 31, 2020. The company said that net revenue for the third quarter of 2020 was $18.1 million, a 10% increase from $16.5 million in the third quarter of 2019. The company delivered a net loss of $3 million.

Flower One Holdings Inc. (CSE: FONE) (OTCQX: FLOOF) announced preliminary third-quarter revenue of $11.5 million surpassing its Q3 2020 revenue guidance range of $9.8 million and $10.8 million. The company did not state whether it had any profits or net losses.

Fundraising is picking up on the private side. Michigan-based privately-owned cannabis company Gage Cannabis Co. has launched a Regulation A, Tier 2, equity financing.  The company’s Executive Chairman is industry leader Bruce Linton. Gage is hoping to raise roughly $49 million. 

 Drop Delivery, a cannabis delivery management solution, raised $1M through equity crowdfunding.

 


StaffStaffOctober 16, 2020
cbd5.jpg

10min8280

Editors Note: This is a guest post.

CBD oil can be used to improve your sleep cycle, inflammation, and digestive system and reduce your chances of getting anxiety.

Suffering from anxiety is natural, especially in times like these where a global pandemic has taken the world by storm

The constant and ongoing stressful atmosphere causes serious damage to your body. Apart from that, it destroys your ability to think, focus, and stay calm.

Stress also causes sleep deprivation, loss of energy, and high blood pressure. For people dealing with all these, CBD oil can work as an absolute miracle. 

With the help of this product, you can now have the opportunity to a healthy mental condition without any harmful side effects.

 

What Is CBD?

Cannabidiol(CBD) can be extracted from cannabis plants, marijuana leaves, and hemp flowers. CBD products act as a natural remedy.

By consuming or using this product you will not get high or have any psychotic reaction. Numerous studies have been carried out on different products of CBD and a quality check has also been approved by the FDA.

Reports say that CBD has less than 0.3 % THC, which is very safe than a lot of other drugs and pills that are taken for mental health.

CBD products are now legally consumed and distributed in many states and countries. The list includes countries like German, Canada, Denmark, Sweden, The USA & The UK.

Just like different brands of marijuana, there are also various brands of CBD oils available.

In the USA you can only use CBD products for medical purposes. It has to be prescribed by a licensed doctor for you to buy and consume it.

If your state has legalized the sale and consumption of cannabis products then it will be easier to find CBD oils in some particular cannabis clinics, shops, and online stores like CBD Oil Uk.

 

 

The Difference Between Stress And Anxiety

Stress is a short-term ailment that can happen regularly or once in a while and does not cause any serious damages. Besides, it can be managed easily. 

If you face problems like frustration, exhaustion, muscle pain, digestive issues, and difficulty sleeping frequently then it is likely you are dealing with stress.

Anxiety is more severe than stress. It can not be alleviated easily. Instead, it is considered as non-stop excessive worry and fear even when everything is perfectly fine in your life.

Anxiety leads to a set of symptoms that are almost identical to stress but very serious. These include insomnia, difficulty in concentration, fatigue, and muscle tension.

It is important to differentiate the signs of stress and anxiety. Stress is a common cause of anxiety and to avoid anxiety symptoms, it is important to catch them early.

How CBD Products Can Help?

Here are 4 ways CBD products can help reduce anxiety and depression-

1.CBD Improves Your Sleep Cycle

People suffering from anxiety often complain about the lack of sleep. 

Excessive anxiety often interrupts your sleep cycle and lack of sleep can, in turn, result in more anxiety.

CBD has claimed to reduce anxiety levels. It has even shown positive results in clinical trials that is why the FDA has approved CBD in the first place. 

CBD helps calm our minds and increases the chances of falling asleep naturally and without any disruption.

Also, studies have proven that little extra dosage of CBD creates a sedative effect on your body and helps to sleep and lets your brain rest. CBD products are now used to treat people with insomnia as well.

 

2.CBD Reduces Pain & Inflammation

Earlier we have discussed that stress and anxiety can cause muscle pain, headaches, and chronic inflammation.

CBD products are completely natural. The products have been proven to be a muscle relaxant and work better than any standard painkillers since it has no side effects. 

CBD also works as anti-inflammatory drugs. It controls cytokine production which is generally responsible for various inflammatory diseases in our body.

This increased inflammation is also connected to higher levels of anxiety. Just like sleep and anxiety, this one is also a chain reaction.

Inflammatory diseases like psoriasis and arthritis can cause depression and anxiety in the long run. CBD oil helps to reduce inflammation and pain by reducing cytokine and affecting CB-2 receptors. This reduces pain and decreases the chance of getting an anxiety attack.

 

3. CBD improves mood

CBD is considered as a “Neuroprotective” material. “Neuroprotective” actually means it will protect nerve cells by keeping a safe functioning state of the nervous system. 

Moreover, it decreases the oxidative stress of your brain.

By keeping your negative emotions in check, CBD helps you to improve your mood and keeps your brain calm and relaxed. It reduces unnecessary stress and anxiety.

 

4. CBD Helps Enhance Metabolism

If you have a poor digestive and metabolism system, it will affect your quality of life. 

It will make you feel bloated and lethargic. Illness disrupts the natural functioning of your body and if it becomes more serious it causes stress and ultimately, leads to anxiety.

If you start consuming CBD regularly, it will improve your metabolism, burn unnecessary fat, and make you feel better.

How To Choose CBD Products?

CBD has various types of products in the market including oil, tablets, edibles, beverages, creams, and vape. Although the overall vape sales slowed down during this year. Things are starting to look better.

But still, the CBD oils are the most popular ones by a large margin.

Each of the types provides almost the same benefits with some unique advantages of their own.

CBD oils have to be consumed daily and provide the most health benefits. They are also the most concentrated ones. 

CBD gummies are sweet and take a long time to take effect. CBD lotions are best for exterior physical discomfort.

Depending on your medical condition, you should consult with a healthcare professional who has experience with CBD to choose the right product.

Final Thoughts

The coronavirus has spread all around the world and claimed the lives of more than one million people. This pandemic is taking its toll on everyone. So it is natural to have anxiety attacks. CBD products may not be able to directly battle the coronavirus but it certainly can help reduce your stress and anxiety.

 

 

 


Kaitlin DomangueKaitlin DomangueOctober 15, 2020
daily_hit004-1280x533.png

5min6000

It’s time for your Daily Hit of cannabis financial news for October 15th, 2020. 

On the Site

MDMA Treatments May Be Cheaper Than Other PTSD Treatments

A peer-reviewed study published in the research journal PLOS ONE demonstrates that MDMA-assisted psychotherapy is remarkably cost-effective when compared to currently available treatments for posttraumatic stress disorder (PTSD). It is estimated that a public healthcare payer or private insurer making MDMA-assisted psychotherapy available to 1,000 patients with PTSD would reduce general and mental health care costs by $103.2 million over 30 years. This treatment has not yet been approved by the FDA, does not work for everyone, and carries risks even in therapeutic settings.

Aphria’s First Quarter Earnings Show Record Gross Revenue for Adult-Use Cannabis

Aphria released their first quarter earnings for fiscal year 2021, and the report shows record breaking gross revenue for adult-use cannabis. The company reported a gross revenue of $69.6 million in the first quarter for fiscal year 2021. This represents strong growth, showing a 23% increase from the prior quarter, as well as the sixth consecutive quarter of growth. Their net cannabis revenue totaled $62.5 million, showing a whopping increase of 103% from the same quarter last year. The company reported an adjusted EBITDA of $10.4 million for cannabis business, representing an 11% increase from the prior quarter.

Akerna Launches POS Software 

Akerna (Nasdaq: KERN) has launched MJ Retail, a first-of-its-kind proprietary software technology designed to provide merchants and consumers with a flexible and mobile-friendly experience. The product is currently available in beta form and will be live in a couple of weeks.

In Other News

MedMen Reports Q4 Earnings and Pre-Announces Q1 2021 Earnings

The net revenue across MedMen’s operations in Nevada, California, New York, Florida, and Illinois reached $27.4 million for the fourth quarter. This is down 40% from the previous quarter, and the company mainly attributes this to COVID-19’s effect on the company’s retail operations. They estimate their Q1 revenue to be $37.4 million, which is a 37% increase from Q4’s earnings on a comparable basis. MedMen’s gross margins increased by 8% from the third to fourth quarter, totaling 40% in Q4. MedMen’s adjusted EBITDA was a loss of $23.3 million for the fourth quarter. 


StaffStaffOctober 15, 2020
shutterstock_551309110.jpg

3min6960

Akerna (Nasdaq: KERN) has launched of MJ Retail, a first-of-its-kind proprietary software technology designed to provide merchants and consumers with a flexible and mobile-friendly experience. The product is currently available in beta form and will be live in a couple of weeks.

“MJ Platform is integral to the success of our clients’ business. Launching MJ Retail was the next logical step to support our growing number of clients who are focused on delivering an exceptional customer experience no matter how customers shop,” said Jessica Billingsley, chief executive officer, Akerna.  “As the in-store experience continues to evolve MJ Retail has been designed to help our clients accelerate and streamline customer checkout, creating an optimal customer experience.”

Akerna said that MJ Retail is an independent POS product that connects to Akerna’s ecosystem for compliance, back office, and reporting functionality. It is specifically designed to provide merchants and consumers with a flexible and mobile-friendly experience by allowing transactions to happen at any time throughout the retail experience on any device.

The company says it benefits the industry since with most POS software platforms, businesses are usually presented with the choice of either a full-featured, data-rich system that requires an investment in training or a simple to use platform that lacks essential features.  MJ Retail says it marries both form and function, that it is easy to use and lightweight, and it does not sacrifice critical data collection and analytics reporting features.

MJ Retail says it gives back to retail workers much needed time, cost, and energy spent on unnecessary clicks. This is something that has benefits that continue long after you begin using it.

Akerna said that for CBD businesses that sign up for Akerna’s payment processing solution MJ Payments, MJ Retail will be made available to them for free. Existing MJ Platform customers will also be able to upgrade to MJ Retail at no cost.



About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

@GreenMarketRpt – 1 day

In case you missed it. Weed Talk News 10/16/2020 via @ProCannaMedia

@GreenMarketRpt – 4 days

Green Market Report’s Marijuana Money October 16, 2020

@GreenMarketRpt – 6 days

Green Market Report Wins Big During 2020 Awards Season

Back to Top

You have Successfully Subscribed!